The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

mRNA Synthesis and Manufacturing Services Market by Type of Products (API and Drug Products), Application Areas (Infectious Disease Vaccines, Other Vaccines, Therapeutics and Others), Scale of Operation (Research / Preclinical, Clinical and Commercial), Geographical Regions (North America , Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    July 2021

  • Pages
    145

  • View Count
    805

Example Insights

mRNA-Synthesis-and-Manufacturing-Market-Context mRNA-Synthesis-and-Manufacturing-Market-Overall-Market-Landscape mRNA-Synthesis-and-Manufacturing-Market-Analysis-by-Scale-of-Operation
mRNA-Synthesis-and-Manufacturing-Market-Distribution-by-Service-Portfolio mRNA-Synthesis-and-Manufacturing-Market-Analysis-by-Type-of-Kits mRNA-Synthesis-and-Manufacturing-Market-Competitiveness-Analysis
mRNA-Synthesis-and-Manufacturing-Market-Partnerships-and-Collaborations mRNA-Synthesis-and-Manufacturing-Market-Big-Pharma-Initiative mRNA-Synthesis-and-Manufacturing-Market-Future-Forecast

 

Overview

The applications of RNA, in both basic research and clinical R&D, have increased after advances in the field of molecular biology have significantly improved the in vitro stability of such molecules. Presently, there are more than 150 therapeutics and vaccines, either based on mRNA molecules, or involve the use of mRNA in their respective production processes, which are being evaluated for the treatment of a wide variety of indications. It is worth highlighting that most of the aforementioned product candidates are in the preclinical stages of development. Prominent examples include dendritic cell vaccines, T cell therapies, other anti-cancer therapies / vaccines, and stem cell therapies, which are modified in vitro using transgenes encoded into mRNA vectors; on the other hand, there are certain novel therapeutic paradigms that are exploring the in vivo transformation of cells using stable mRNAs (carrying therapeutic gene segments) that are delivered via viable nanocarriers. In fact, the first two of the vaccines to be approved (Pfizer / BioNTech’s BNT-162 and Moderna’s mRNA-1273) against the SARS-CoV-2 viral pathogen, were based on mRNA and have recently been approved for use across various global regions. According to the CDC, more than 374 million doses of vaccines have been delivered in the US alone. 

The success of the anti-COVID-19 vaccines has created an enormous need for consistent supply of these new vaccines; for instance, Pfizer needs to deliver 1.6 billion doses and Moderna needs to produce between 800 million to 1 billion doses of their respective products by the end of 2021. As a result, there is an evident increase in demand for mRNA manufacturing capacity. Fundamentally, the production of this biomolecule is complex, cost intensive and requires specialized expertise. In addition, scaling up the manufacturing of RNA is also associated with a number of challenges, mostly related to process development, and maintaining purity and stability. Referring to scaling up of manufacturing activities to meet pandemic level requirements, Tanya Alcorn, Vice President of Pfizer’s biopharmaceutical global supply chain, recently identified the need for harmony in the efforts of the various stakeholders (suppliers and manufacturing teams) in order to adequately amplify production output. Moreover, some of the processes associated with mRNA production, such as the purification step, involve the use of hazardous solvents / materials. Once manufactured, mRNA therapeutics need to be stored in conditions that do not compromise their stability (thereby, requiring specialized facilities and cold chain transportation); they also require appropriate drug delivery systems to efficiently administer the intervention (in a manner that they can avoid degradation by cellular endonucleases). Given such technical and operational challenges associated with the production of RNA-based products, innovators in the biopharmaceutical industry are increasingly leaning on contract service providers. Moreover, the COVID-19 pandemic has caused a notable surge in outsourcing activity, with vaccines developers entering into strategic deals with contract service providers to cater to the urgent global demand. The services landscape features a mix of large, mid-sized and small companies, which claim to have mRNA-related capabilities. Recent developments in this segment of the biopharmaceutical industry indicate that service providers are upgrading their capabilities and infrastructure to accommodate the current and anticipated demand for this novel class of biologics. In the foreseen future, as more of such RNA-based leads mature and move into the clinic and / or the market, we anticipate the mRNA synthesis service providers market to witness healthy growth.

Scope of the Report

The “mRNA Synthesis and Manufacturing Market, 2021-2030” report features an extensive study of the current market landscape and future opportunity for the players involved in the synthesis of research- and GMP-grade mRNA for use in development of therapeutics and vaccines. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:

  • A review of the overall market landscape of mRNA synthesis service providers  (custom synthesis service providers and cGMP service providers), including analysis based on the services offered (custom synthesis, modification, purification, process development, scale-up / manufacturing, formulation and fill / finish), type of modification (3’ modification, 5’ modification, base modification), types of purification techniques (precipitation, chromatography, electrophoresis and others ), input data for synthesis (plasmid DNA, mRNA sequence, PCR fragments and others), scale of operation (research / preclinical, clinical and commercial), GMP compliance, and mRNA specifications (length  and quantity). In addition, the chapter provides the list of companies involved in the development of custom mRNA synthesis kits along with information on kit type, number of reactions, type of enzyme, incubation time, cap included, modified bases included, yield and price.
  • Elaborate profiles of key players engaged in the synthesis of mRNA (shortlisted based on strength of service portfolio). Each profile includes a brief overview of the company, mRNA synthesis service highlights, information on additional services offered, recent developments and an informed future outlook (if any). Additionally, the chapter also includes profiles of the key mRNA synthesis kits providers (shortlisted based on strength of product portfolio).
  • An insightful company competitiveness analysis, highlighting prominent custom mRNA service providers, based on supplier strength (based on the company’s employee count), service portfolio strength (which takes into account the number of services offered by the company), scale of operation and geographical location of the company.
  • An analysis of the partnerships and collaborations that have been established since 2014, covering manufacturing agreements, supply agreements, acquisitions, technology development agreements, and other relevant deals. The chapter includes analysis based on various parameters, such as year of partnership, type of partnership model, geographical distribution of partnering activity and most active players (in terms of number of partnerships inked) in this domain. 
  • An analysis of the initiatives related to mRNA, undertaken by big pharma players, based on parameters, including number of initiatives, year of initiative and the type of initiative.
  • A detailed analysis of completed, ongoing and planned clinical trials of mRNA-based therapeutics and vaccines taking into consideration several relevant parameters, such as trial registration year, number of patients enrolled, gender of patients enrolled, trial phase, recruitment status, and study design, highlighting the leading players (in terms of number of trials conducted), type of organization, key therapeutic areas and regional distribution of trials.
  • An informed estimate of the current annual demand of the marketed mRNA-based  products (in grams); the analysis takes into consideration the number of doses ordered, dosing frequency and dose strength of the products. The annual clinical demand of mRNA-based drug products was also estimated based on parameters, such as ongoing and planned clinical trials, enrolled number of participants (if available), quantity of mRNA used in each dose and number of doses.

One of the key objectives of the report was to estimate the future growth potential of mRNA synthesis services market, over the coming decade. Based on multiple parameters, such as mRNA products market, cost of goods sold, manufacturing cost and share of outsourcing, we have provided an informed estimate on the evolution of the market for the period 2021-2030.  The report features the likely distribution of the current and forecasted opportunity across [A] Type of Products (API and drug products) [B] Application Areas (Infectious Disease Vaccines, Other Vaccines, Therapeutics and Others), [C] Scale of Operation (Research / Preclinical, Clinical and Commercial), [D] Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry’s growth.

Key Questions Answered

  • Who are the key service providers engaged in the custom synthesis of research-grade mRNA?
  • Who are the key service providers engaged in the manufacturing, formulation and fill/finish of GMP-grade mRNA?
  • Which regions are current hubs for GMP grade production of mRNA?
  • Which companies are actively involved in conducting clinical trials for their mRNA-based therapeutics and vaccines? 
  • Which regions are leading the enrollment of patients in mRNA-based therapeutics and vaccines clinical trials?
  • Which partnership models are commonly adopted by stakeholders engaged in this domain?
  • Which factors are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the mRNA synthesis services market and its likely evolution in the short-mid to long term.

Chapter 3 provides a general introduction to mRNA synthesis. In addition, we have briefly described the advantages of mRNA, different mechanisms of mRNA synthesis and its therapeutic applications. The chapter lays emphasis on the in-vitro synthesis of mRNA and its applications in various therapeutic modalities. It also includes a discussion on the commonly outsourced manufacturing operations and its advantages.

Chapter 4 includes a detailed analysis of the current market landscape of mRNA synthesis service providers (custom synthesis service providers and cGMP service providers), based on  the services offered (custom synthesis, modification, purification, process development, scale-up / manufacturing, formulation and fill/finish), type of modification (3’ modification, 5’ modification, base modification), types of purification (precipitation, chromatography, electrophoresis and others ), input data for synthesis (plasmid DNA, mRNA sequence, PCR fragments and others), scale of operation (research / preclinical, clinical, commercial), GMP compliance, and mRNA specifications (length  and quantity). In addition, the chapter provides the list of companies involved in the development of  custom mRNA synthesis kits, along with information on kit type, number of reactions, type of enzyme, incubation time, cap included , modified bases included, yield and price.

Chapter 5 features an insightful company competitiveness analysis of the players engaged in custom synthesis of mRNA, based on the services offered, company size, location of headquarters and scale of operation

Chapter 6 presents a detailed analysis of clinical trials registered for mRNA-based therapeutics and vaccines, based on several relevant parameters, such as trial registration year, number of patients enrolled, trial phase, recruitment status, and study design, highlighting the leading players (in terms of number of trials conducted), type of organization, key therapeutic areas and regional distribution of trials.

Chapter 7 features a detailed analysis of the partnerships and collaborations that have been established since 2014, covering manufacturing agreements, supply agreements, acquisitions, technology development agreements, and other relevant deals. The chapter includes analysis based on year of partnership, type of partnership model, geographical distribution of partnering activity and most active player(s) (in terms of number of partnerships inked) in this domain. 

Chapter 8 provides a detailed analysis of the various initiatives related to the mRNA synthesis, undertaken by big pharma players, based on parameters, including number of initiatives, year of initiative, purpose of initiative and type of initiative.

Chapter 9 includes profiles of the key players engaged in the synthesis of mRNA (shortlisted based on strength of service portfolio). Each profile includes a brief overview of the company, mRNA synthesis service highlights, information on additional services offered, recent developments and informed future outlook (if any). Additionally, the chapter includes profiles of the key  mRNA synthesis kits providers (shortlisted based on number of synthesis kits offered).

Chapter 10 provides estimate of the demand for mRNA-based products (expressed in grams of mRNA required). For estimating the current clinical demand, we considered the active clinical studies of vaccines, which have been registered since 2020. The data was analyzed based on several parameters, such as type of vaccines, dosage of vaccine, frequency of dosage and geography across which the demand was calculated. Similarly, the commercial demand was calculated by considering the annual volume of vaccine doses sold, based on parameters, such as types of vaccines, number of doses ordered and geography across which the demand was calculated

Chapter 11 features an elaborate discussion on the future potential of the mRNA synthesis services market. The chapter provides insights on the likely distribution of the current and forecasted opportunity across [A] Type of Products (API and Drug Products) [B] Application Areas (Infectious Disease Vaccines, Other Vaccines, Therapeutics and Others), [C] Scale of Operation (Research / Preclinical, Clinical and Commercial), [D] Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World).

Chapter 12 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Structure of Mature mRNA
3.2. Chemical Synthesis of mRNA
3.3. Drawbacks of Chemical Synthesis
3.4. In vitro Synthesis of mRNA 
3.5. Purification of Synthesized mRNA
3.6. Applications of in vitro Synthesized mRNA
3.7. Commonly Outsourced Manufacturing Operations
3.8. Advantages of Outsourcing Manufacturing Operations

4. MARKET LANDSCAPE
4.1. Market Landscape of mRNA Synthesis Custom Service Providers
4.1.1. Analysis by Year of Establishment
4.1.2. Analysis by Company Size
4.1.3. Analysis by Location of Headquarters
4.1.4. Analysis by Type of Service(s) Offered
4.1.5. Analysis by Input for Synthesis
4.1.6. Analysis by Scale of Operation
4.1.7. Analysis by Type of Purification Method
4.1.8. Analysis by GMP Compliance
4.1.9. Analysis by Application Area
4.1.10. Grid Analysis by Scale of Operation and Application Area

4.2. Market Landscape of cGMP Service Providers
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Player
4.2.5. Analysis by Type of Service(s) Offered
4.2.6. Leading Partners: Analysis by Number of Service Partners
4.2.7. Location of mRNA Facilities

4.3. Market Landscape of mRNA Synthesis Kits
4.3.1. Analysis by Type of Kit
4.3.2. Analysis by Reaction Time
4.3.3. Analysis by Number of Reactions
4.3.4. Analysis by Type of Enzyme
4.3.5. Analysis by Type of Cap Included
4.3.6. Analysis by Type of Modified Bases Included
4.3.7 Analysis by Yield per Reaction
4.3.8 Analysis by Price Range
4.3.9 Analysis by Yield and Price Range

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Methodology
5.2. Competitiveness Analysis: Leading mRNA Custom Synthesis Service Providers in North America
5.3. Competitiveness Analysis: Leading mRNA Synthesis Service Providers in Europe
5.4. Competitiveness Analysis: Leading mRNA Synthesis Service Providers in Asia Pacific

6 CLINICAL TRIAL ANALYSIS
6.1. Methodology
6.2 mRNA-based Products: Clinical Trial Analysis
6.2.1 Analysis by Trial Status
6.2.2 Analysis by Trial Registration Year
6.2.3 Analysis by Trial Phase
6.2.4 Analysis by Therapeutic Area
6.2.5 Analysis by Type of Sponsor
6.2.6 Geographical Analysis by Trial Status
6.2.7 Analysis by Trial Phase and Patients Enrolled
6.2.8 Analysis by Location of Trial Site and Patients Enrolled
6.2.9 Analysis by Purpose of Study
6.2.10 Analysis by Allocation
6.2.11 Analysis by Patient Segment

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Analysis by Year of Partnership
7.2. Analysis by Type of Partnership Model
7.3. Most Active Players: Analysis by Number of Partnerships
7.4. Intercontinental and Intracontinental Agreements
7.5. Local and International Agreements
7.6. Top Partners: Analysis by Number of Partnerships

8. BIG PHARMA INITIATIVES
8.1. Analysis by Type of Initiative
8.2. Analysis by Therapeutic Focus
8.3. Analysis by Number of Partnerships

9. COMPANY PROFILES
9.1. Eurogentec
9.1.1. Company Overview
9.1.2. mRNA Synthesis Service Highlights
9.1.3. mRNA Service Portfolio
9.1.4. Recent Developments
9.1.5. Future Outlook

9.2. Aldevron
9.2.1. Company Overview
9.2.2. mRNA Synthesis Service Highlights
9.2.3. mRNA Service Portfolio
9.2.4. Recent Developments
9.2.5. Future Outlook

9.3. eTheRNA
9.3.1. Company Overview
9.3.2. mRNA Synthesis Service Highlights
9.3.3. mRNA Service Portfolio
9.3.4. Recent Developments
9.3.5. Future Outlook

9.4. bioSYNTHESIS
9.4.1. Company Overview
9.4.2. mRNA Synthesis Service Highlights
9.4.3. mRNA Service Portfolio
9.4.4. Recent Developments
9.4.5. Future Outlook

9.5. TriLink BioTechnologies
9.5.1. Company Overview
9.5.2. mRNA Synthesis Service Highlights
9.5.3. mRNA Service Portfolio
9.5.4. Recent Developments
9.5.5. Future Outlook
9.6. Biomay
9.6.1. Company Overview
9.6.2. mRNA Synthesis Service Highlights
9.6.3. mRNA Service Portfolio
9.6.4. Recent Developments
9.6.5. Future Outlook

9.7 Jena Biosciences
9.7.1. Company Overview
9.7.2. Kit Overview
9.7.3. Kit Specifications
9.7.4. Application Areas

9.8 APExBIO
9.8.1. Company Overview
9.8.2. Kit Overview
9.8.3. Kit Specifications
9.8.4. Application Areas

9.9. CELLSCRIPT
9.9.1. Company Overview
9.9.2. Kit Overview
9.9.3. Kit Specifications
9.9.4. Application Areas

9.10. Thermo Fisher Scientific
9.10.1. Company Overview
9.10.2. Kit Overview
9.10.3. Kit Specifications
9.10.4. Application Areas

9.11. New England Biolabs
9.11.1. Company Overview
9.11.2. Kit Overview
9.11.3. Kit Specifications
9.11.4. Application Areas

10. DEMAND ANALYSIS
10.1. Methodology and Assumption
10.2. Global mRNA Demand: Clinical and Commercial, 2021
10.3. Global Commercial Demand for mRNA, 2020 and 2021
10.3.1. Analysis by Geography
10.3.2. Analysis by Developer
10.4. Global Clinical Demand for mRNA, 2020 and 2021
10.4.1. Analysis by Geography
10.4.2. Analysis by Phase of Development

11. MARKET FORECAST
11.1. Methodology and Assumption
11.2. Overall mRNA Synthesis and Manufacturing Market, 2021-2030
11.2.1. mRNA Synthesis and Manufacturing Market, 2021-2030: Distribution by Type of Product
11.2.2. mRNA Synthesis and Manufacturing Market, 2021-2030: Distribution by Application Area
11.2.3. mRNA Synthesis and Manufacturing Market, 2021-2030: Distribution by Scale of Operation
11.2.4. mRNA Synthesis and Manufacturing Market, 2021-2030: Distribution by Geography
11.3. mRNA Synthesis and Manufacturing Market in North America, 2021-2030
11.3.1. mRNA Synthesis and Manufacturing Market in North America, 2021-2030: Distribution by Type of Product
11.3.2. mRNA Synthesis and Manufacturing Market in North America, 2021-2030: Distribution by Application Area
11.3.3. mRNA Synthesis and Manufacturing Market in North America, 2021-2030: Distribution by Scale of Operation
11.4. mRNA Synthesis and Manufacturing Market in Europe, 2021-2030
11.4.1. mRNA Synthesis and Manufacturing Market in Europe, 2021-2030: Distribution by Type of Product
11.4.2. mRNA Synthesis and Manufacturing Market in Europe, 2021-2030: Distribution by Application Area
11.4.3. mRNA Synthesis and Manufacturing Market in Europe, 2021-2030: Distribution by Scale of Operation
11.5. mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2021-2030
11.5.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of Product
11.5.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Application Area
11.5.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
11.6. mRNA Synthesis and Manufacturing Market in Rest of the World 2021-2030
11.6.1. mRNA Synthesis and Manufacturing Market in Rest of the World, 2021-2030: Distribution by Type of Product
11.6.2. mRNA Synthesis and Manufacturing Market in Rest of the World, 2021-2030: Distribution by Application Area
11.6.3. mRNA Synthesis and Manufacturing Market in Rest of the World, 2021-2030: Distribution by Scale of Operation

12. APPENDIX 1: TABULATED DATA 

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS 

List Of Figures

Figure 3.1 Structure of Mature mRNA
Figure 3.2 Chemical Synthesis of mRNA
Figure 3.3 Drawbacks of Chemical Synthesis
Figure 3.4 In vitro Synthesis of mRNA
Figure 3.5 Purification of Synthesized mRNA
Figure 3.6 Applications of in vitro Synthesized mRNA
Figure 3.7 Commonly Outsourced Manufacturing Operations
Figure 3.8 Advantages of Outsourcing Manufacturing Operations
Figure 4.1 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Year of Establishment
Figure 4.2 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Company Size
Figure 4.3 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Location of Headquarters
Figure 4.4 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Type of Service(s) Offered
Figure 4.5 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Input for Synthesis
Figure 4.6 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Scale of Operation
Figure 4.7 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Type of Purification Method
Figure 4.8 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by GMP Compliance
Figure 4.9 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Application Area
Figure 4.10 mRNA Synthesis and Manufacturing Custom Service Providers: Grid Analysis by Scale of Operation and Application Area
Figure 4.11 mRNA Synthesis and Manufacturing cGMP Service Providers: Distribution by Year of Establishment
Figure 4.12 mRNA Synthesis and Manufacturing cGMP Service Providers: Distribution by Company Size
Figure 4.13 mRNA Synthesis and Manufacturing cGMP Service Providers: Distribution by Location of Headquarters
Figure 4.14 mRNA Synthesis and Manufacturing cGMP Service Providers: Distribution by Type of Player
Figure 4.15 mRNA Synthesis and Manufacturing cGMP Service Providers: Distribution by Type of Service(s) Offered
Figure 4.16 mRNA Synthesis and Manufacturing cGMP Service Providers: Leading Partners
Figure 4.17 mRNA Synthesis and Manufacturing cGMP Service Providers: Location of mRNA Facilities
Figure 4.18 mRNA Synthesis Kits: Distribution by Type of Kit
Figure 4.19 mRNA Synthesis Kits: Distribution by Reaction Time
Figure 4.20 mRNA Synthesis Kits: Distribution by Number of Reactions
Figure 4.21 mRNA Synthesis Kits: Distribution by Type of Enzyme
Figure 4.22 mRNA Synthesis Kits: Distribution by Type of Cap Included
Figure 4.23 mRNA Synthesis Kits: Distribution by Type of Modified Bases Included
Figure 4.24 mRNA Synthesis Kits: Distribution by Yield per Reaction
Figure 4.25 mRNA Synthesis Kits: Distribution by Price Range
Figure 4.26 mRNA Synthesis Kits: Distribution by Yield and Price Range
Figure 5.1 mRNA Synthesis and Manufacturing Custom Service Providers: 4 Parameter Bubble Analysis
Figure 5.2 mRNA Synthesis and Manufacturing Custom Service Providers: Leading Players in North America
Figure 5.3 mRNA Synthesis and Manufacturing Custom Service Providers: Leading Players in Europe
Figure 5.4 mRNA Synthesis and Manufacturing Custom Service Providers: Leading Players in Asia-Pacific
Figure 6.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Registration Year
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.4 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 6.5 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 6.6 Clinical Trial Analysis: Geographical Distribution by Trial Status
Figure 6.7 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Figure 6.8 Clinical Trial Analysis: Distribution by Location of Trial Site and Patients Enrolled
Figure 6.9 Clinical Trial Analysis: Distribution by Purpose of Study
Figure 6.10 Clinical Trial Analysis: Distribution by Allocation
Figure 6.11 Clinical Trial Analysis: Distribution by Patient Segment
Figure 7.1 Partnerships and Collaborations: Year-Wise Cumulative Trend (2014 – April 2021)
Figure 7.2 Partnerships and Collaborations: Analysis by Type of Partnership Model
Figure 7.3 Most Active Players (Number of Instances)
Figure 7.4 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 7.5 Partnerships and Collaborations: Local and International Agreements
Figure 7.6 Partnerships and Collaborations: Top Partners (Number of Instances)
Figure 8.1 Big Pharma Initiatives (Partnerships): Distribution by Type of Initiative
Figure 8.2 Big Pharma Initiatives (Partnerships): Distribution by Therapeutic Focus
Figure 8.3 Top Big Pharma Players: Analysis by Number of Partnerships
Figure 10.1. Global mRNA Demand: Clinical and Commercial, 2021 (Kilograms)
Figure 10.2. Global Commercial Demand for mRNA, 2020 and 2021 (Kilograms)
Figure 10.3. Global Commercial Demand for mRNA, 2020 and 2021: Distribution by Region (Kilograms)
Figure 10.4. Global Commercial Demand for mRNA, 2020 and 2021: Distribution by Developer (Kilograms)
Figure 10.5. Global Clinical Demand for mRNA, 2020 and 2021 (Kilograms)
Figure 10.6 Global Clinical Demand for mRNA, 2020 and 2021: Distribution by Region (Kilograms)
Figure 10.7 Global Clinical Demand for mRNA, 2020 and 2021: Distribution by Phase of Development (Kilograms)
Figure 11.1 Overall mRNA Synthesis and Manufacturing Market, 2021-2030
Figure 11.2 mRNA Synthesis and Manufacturing Market, 2021-2030: Distribution by Type of Product
Figure 11.3 mRNA Synthesis and Manufacturing Market, 2021-2030: Distribution by Application Area
Figure 11.4 mRNA Synthesis and Manufacturing Market, 2021-2030: Distribution by Scale of Operation
Figure 11.5 mRNA Synthesis and Manufacturing Market, 2021-2030: Distribution by Geography
Figure 11.6 mRNA Synthesis and Manufacturing Market in North America, 2021-2030
Figure 11.7 mRNA Synthesis and Manufacturing Market in North America, 2021-2030: Distribution by Type of Product
Figure 11.8 mRNA Synthesis and Manufacturing Market in North America, 2021-2030: Distribution by Application Area
Figure 11.9 mRNA Synthesis and Manufacturing Market in North America, 2021-2030: Distribution by Scale of Operation
Figure 11.10 mRNA Synthesis and Manufacturing Market in Europe, 2021-2030
Figure 11.11 mRNA Synthesis and Manufacturing Market in Europe, 2021-2030: Distribution by Type of Product
Figure 11.12 mRNA Synthesis and Manufacturing Market in Europe, 2021-2030: Distribution by Application Area
Figure 11.13 mRNA Synthesis and Manufacturing Market in Europe, 2021-2030: Distribution by Scale of Operation
Figure 11.14 mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2021-2030
Figure 11.15 mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of Product (USD Million)
Figure 11.16 mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of Application Area
Figure 11.17 mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 11.18 mRNA Synthesis and Manufacturing Market in Rest of the World, 2021-2030 (USD Million)
Figure 11.19 mRNA Synthesis and Manufacturing Market in Rest of the World, 2021-2030: Distribution by Type of Product (USD Million)
Figure 11.20 mRNA Synthesis and Manufacturing Market in Rest of the World, 2021-2030: Distribution by Type of Application Area
Figure 11.21 mRNA Synthesis and Manufacturing Market in Rest of the World, 2021-2030: Distribution by Scale of Operation (USD Million)

List Of Tables

Table 4.1 mRNA Synthesis and Manufacturing: List of Custom Synthesis Service Providers
Table 4.2 mRNA Synthesis and Manufacturing Custom Service Providers: Information on Synthesis / Manufacturing Capacity
Table 4.3 mRNA Synthesis and Manufacturing Custom Service Providers: Information on Type of Modifications Offered
Table 4.4 mRNA Synthesis and Manufacturing Custom Service Providers: Information on Purification Methods Used
Table 4.5 mRNA Synthesis and Manufacturing Custom Service Providers: Information on Synthesis Input Required
Table 4.6 mRNA Synthesis and Manufacturing: List of cGMP Service Providers
Table 4.7 mRNA Synthesis and Manufacturing: List of Kit Providers
Table 4.8 mRNA Synthesis and Manufacturing Kit Providers: Information on Company, Kit Type, Number of Reactions, Type of Enzyme, Reaction Time and Cap Included
Table 4.9 mRNA Synthesis and Manufacturing Kit Providers: Information on Modified Bases Included, Yield, Price, Purification Feature, Additional Benefits
Table 5.1 mRNA Synthesis and Manufacturing Service Providers: List of Clinical Trials
Table 7.1 mRNA Synthesis and Manufacturing Services Market: Partnerships and Collaborations
Table 8.1 mRNA-based Products: Deals Inked by Big Pharma Companies
Table 12.1 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Year of Establishment
Table 12.2 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Company Size
Table 12.3 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Location of Headquarters
Table 12.4 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Type of Service(s) Offered
Table 12.5 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Input for Synthesis
Table 12.6 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Scale of Operation
Table 12.7 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Type of Purification Method
Table 12.8 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by GMP Compliance
Table 12.9 mRNA Synthesis and Manufacturing Custom Service Providers: Distribution by Application Area
Table 12.10 mRNA Synthesis and Manufacturing Custom Service Providers: Grid Analysis by Scale of Operation and Application Area
Table 12.11 mRNA Synthesis and Manufacturing cGMP Service Providers: Distribution by Year of Establishment
Table 12.12 mRNA Synthesis and Manufacturing cGMP Service Providers: Distribution by Company Size
Table 12.13 mRNA Synthesis and Manufacturing cGMP Service Providers: Distribution by Location of Headquarters
Table 12.14 mRNA Synthesis and Manufacturing cGMP Service Providers: Distribution by Type of Player
Table 12.15 mRNA Synthesis and Manufacturing cGMP Service Providers: Distribution by Type of Service(s) Offered
Table 12.16 mRNA Synthesis and Manufacturing cGMP Service Providers: Leading Partners
Table 12.17 mRNA Synthesis and Manufacturing cGMP Service Providers: Location of mRNA Facilities
Table 12.18 mRNA Synthesis Kits: Distribution by Type of Kit
Table 12.19 mRNA Synthesis Kits: Distribution by Reaction Time
Table 12.20 mRNA Synthesis Kits: Distribution by Number of Reactions
Table 12.21 mRNA Synthesis Kits: Distribution by Type of Enzyme
Table 12.22 mRNA Synthesis Kits: Distribution by Type of Cap Included
Table 12.23 mRNA Synthesis Kits: Distribution by Type of Modified Bases Included
Table 12.24 mRNA Synthesis Kits: Distribution by Yield per Reaction
Table 12.25 mRNA Synthesis Kits: Distribution by Price Range
Table 12.26 mRNA Synthesis Kits: Distribution by Yield and Price Range
Table 12.27 mRNA Synthesis and Manufacturing Custom Service Providers: 4 Parameter Bubble Analysis
Table 12.28 mRNA Synthesis and Manufacturing Custom Service Providers: Leading Players in North America
Table 12.29 mRNA Synthesis and Manufacturing Custom Service Providers: Leading Players in Europe
Table 12.30 mRNA Synthesis and Manufacturing Custom Service Providers: Leading Players in Asia-Pacific
Table 12.31 Clinical Trial Analysis: Distribution by Trial Status
Table 12.32 Clinical Trial Analysis: Cumulative Distribution by Registration Year
Table 12.33 Clinical Trial Analysis: Distribution by Trial Phase
Table 12.34 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 12.35 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 12.36 Clinical Trial Analysis: Geographical Distribution by Trial Status
Table 12.37 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Table 12.38 Clinical Trial Analysis: Distribution by Location of Trial Site and Patients Enrolled
Table 12.39 Clinical Trial Analysis: Distribution by Purpose of Study
Table 12.40 Clinical Trial Analysis: Distribution by Allocation
Table 12.41 Clinical Trial Analysis: Distribution by Patient Segment
Table 12.42 Partnerships and Collaborations: Year-Wise Cumulative Trend (2014 – April 2021)
Table 12.43 Partnerships and Collaborations: Analysis by Type of Partnership Model
Table 12.44 Partnerships and Collaborations: Most Active Players (Number of Instances)
Table 12.45 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 12.46 Partnerships and Collaborations: Local and International Agreements
Table 12.47 Partnerships and Collaborations: Top Partners (Number of Instances)
Table 12.48 Big Pharma Initiatives (Partnerships): Distribution by Type of Initiative
Table 12.49 Big Pharma Initiatives (Partnerships): Distribution by Therapeutic Focus
Table 12.50 Top Big Pharma Players: Analysis by Number of Partnerships
Table 12.51 Global mRNA Demand: Clinical and Commercial, 2021
Table 12.52 Global Commercial Demand for mRNA, 2020 and 2021 (Kilograms)
Table 12.53 Global Commercial Demand for mRNA, 2020 and 2021: Distribution by Region (Kilograms)
Table 12.54 Global Commercial Demand for mRNA, 2020 and 2021: Distribution by Developer (Kilograms)
Table 12.55 Global Clinical Demand for mRNA, 2020 and 2021 (Kilograms)
Table 12.56 Global Clinical Demand for mRNA, 2020 and 2021: Distribution by Region (Kilograms)
Table 12.57 Global Clinical Demand for mRNA, 2020 and 2021: Distribution by Phase of Development (Kilograms)
Table 12.58 Overall mRNA Synthesis and Manufacturing Market, 2021-2030 (USD Million)
Table 12.59 mRNA Synthesis and Manufacturing Market, 2021-2030: Distribution by Type of Product (USD Million)
Table 12.60 mRNA Synthesis and Manufacturing Market, 2021-2030: Distribution by Application Area (USD Million)
Table 12.61 mRNA Synthesis and Manufacturing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 12.62 mRNA Synthesis and Manufacturing Market, 2021-2030: Distribution by Geography (USD Million)
Table 12.63 mRNA Synthesis and Manufacturing Market in North America, 2021-2030 (USD Million)
Table 12.64 mRNA Synthesis and Manufacturing Market in North America, 2021-2030: Distribution by Type of Product (USD Million)
Table 12.65 mRNA Synthesis and Manufacturing Market in North America, 2021-2030: Distribution by Application Area (USD Million)
Table 12.66 mRNA Synthesis and Manufacturing Market in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 12.67 mRNA Synthesis and Manufacturing Market in Europe, 2021-2030 (USD Million)
Table 12.68 mRNA Synthesis and Manufacturing Market in Europe, 2021-2030: Distribution by Type of Product (USD Million)
Table 12.69 mRNA Synthesis and Manufacturing Market in Europe, 2021-2030: Distribution by Application Area (USD Million)
Table 12.70 mRNA Synthesis and Manufacturing Market in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 12.71 mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2021-2030 (USD Million)
Table 12.72 mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of Product (USD Million)
Table 12.73 mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of Application Area (USD Million)
Table 12.74 mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 12.75 mRNA Synthesis and Manufacturing Market in Rest of the World, 2021-2030 (USD Million)
Table 12.76 mRNA Synthesis and Manufacturing Market in Rest of the World, 2021-2030: Distribution by Type of Product (USD Million)
Table 12.77 mRNA Synthesis and Manufacturing Market in Rest of the World, 2021-2030: Distribution by Type of Application Area (USD Million)
Table 12.78 mRNA Synthesis and Manufacturing Market in Rest of the World, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 12.79 mRNA Synthesis and Manufacturing Market Opportunity, Optimistic Scenario 2021-2030 (USD Million)
Table 12.80 mRNA Synthesis and Manufacturing Market Opportunity, Conservative Scenario 2021-2030 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. Abogen Biosciences
  2. Albany Molecular Research
  3. Aldevron
  4. Allele Biotechnology
  5. AmpTec
  6. AMSBIO
  7. APExBIO
  8. Arcturus Therapeutics
  9. Asterias Biotherapeutics
  10. AstraZeneca
  11. Atrium Health
  12. Baxter BioPharma Solutions
  13. Bayer
  14. Beijing Tricision Biotherapeutics
  15. BIA Separations
  16. Biological E.
  17. Biomay
  18. Bioneer
  19. BioNTech
  20. BioNtech IMFS 
  21. bioSYNTHESIS
  22. Bioverativ
  23. bluebird bio
  24. Boehringer Ingelheim
  25. Bristol-Myers Squibb
  26. Calimmune
  27. Catalent
  28. CELLSCRIPT
  29. Celldex Therapeutics
  30. Cellerna
  31. Chiesi Farmaceutici
  32. China Grand Pharmaceutical and Healthcare Holdings
  33. click biosystems
  34. CMC Pharmaceuticals
  35. Creative Biogene
  36. Creative Biolabs
  37. CureSearch
  38. CureVac
  39. Delpharm
  40. Dermapharm
  41. Eli Lilly
  42. Elixirgen Therapeutics
  43. Enzynomics
  44. etheRNA
  45. Ethris
  46. Eurofins Genomics
  47. Eurogentec
  48. Fareva 
  49. Fosun Pharma
  50. GC Pharma 
  51. Genentech
  52. GenePharma
  53. GenIbet
  54. Gilead
  55. GlaxoSmithKline
  56. Gritstone Oncology
  57. GSL Biotech
  58. Hanmi Pharmaceutical
  59. Immatics Biotechnologies
  60. Immunomic Therapeutics
  61. Integrate RNA
  62. Intellia Therapeutics
  63. Iovance Biotherapeutics
  64. Jacobson Pharma
  65. Jena Bioscience
  66. Laboratorios Farmacéuticos ROVI
  67. LakePharma
  68. Lion TCR
  69. Lonza
  70. Mayo Clinic
  71. MedImmune
  72. Merck
  73. Merck Sharp & Dohme
  74. Moderna
  75. New England Biolabs
  76. Novartis
  77. Novo Nordisk
  78. OZ Biosciences                                                      
  79. Pfizer
  80. PharmaJet
  81. phaRNA
  82. PhaseRx
  83. Providence Therapeutics
  84. RD Biotech
  85. Recipharm
  86. Regeneron Pharmaceuticals
  87. Rentschler Biopharma
  88. RiboPro
  89. Roche 
  90. Roivant Sciences
  91. Samsung Biologics
  92. Sanofi
  93. Sanofi Pasteur
  94. Sartorius
  95. SeouLin Bioscience
  96. Shanghai BD Gene Therapeutics
  97. Siegfried
  98. ST Pharm
  99. Stemirna Therapeutics
  100. Synbio Technologies
  101. Syneos Health
  102. System Biosciences
  103. Takeda Pharmaceuticals
  104. Tesla
  105. Thermo Fisher Scientific
  106. Translate Bio
  107. TriLink Biotechnologies
  108. VGXI
  109. WACKER Chemie
  110. Walvax Biotechnology
  111. Ximedica

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com